Heart drug safety check: does argatroban alter heart rhythms?
NCT ID NCT05740371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 study looked at whether the blood thinner argatroban causes heart rhythm changes (QTc prolongation) in 50 patients with stable coronary artery disease or unstable angina during angioplasty. Patients received argatroban by IV and had ECGs before and after the procedure. The main goal was to see if the QTc interval increased by more than 10 milliseconds, which could signal a risk for dangerous heart rhythms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Argatroban (a blood thinner given by IV)
- What this could lead to
- If successful, this could confirm that argatroban is safe to use during heart procedures without causing dangerous heart rhythm changes.
- What could go wrong
- This is a small, completed Phase 4 safety study with only 50 participants, so results may not apply to all patients. It does not test whether argatroban improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STABLE CORONARY ARTERY DISEASE CAD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Herz-Kreislauf-Zentrum Klinikum Hersfeld-Rotenburg
Rotenburg an der Fulda, Hesse, 36199, Germany
-
University Hospital Frankfurt
Frankfurt am Main, Hesse, 60590, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.